Navigation Links
Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Date:11/12/2007

Researcher at American Academy of Ophthalmology Annual Meeting Describes

Advance in Treatment of Endothelial Disease

NEW ORLEANS, Nov. 12 /PRNewswire/ -- In a research presentation today at the American Academy of Ophthalmology's Annual Meeting, Massimo Busin, MD, department head and professor of ophthalmology at the Villa Serena Hospital, Forli, Italy, described a technique that significantly improved results in patients being treated for endothelial disease of the cornea, the transparent covering of the front of the eye that provides much of its optical power. When the cell density in the endothelial layer is reduced below a level compatible with its normal function, the cornea swells and becomes less transparent, and vision is impaired.

Since endothelial cells do not regenerate, the disease is treated by transplanting healthy donor tissue. The standard approach has been complete cornea transplantation (PK, or penetrating keratoplasy). Today, DSAEK (descemet-stripping automated endothelial keratoplasy)---where only endothelial tissue attached to a thin layer of deep stroma is transplanted and the normal structure of the recipient cornea is not disrupted--is increasingly preferred by corneal surgeons. Most patients receiving DSAEK recover good vision within weeks (versus six months to a year with PK), and the risk of complications during and after surgery is minimized. A significant drawback of DSAEK, though, has been the limited survival of the transplanted endothelium, with a reduction of up to 50 % of preoperative density as early as six months after DSAEK.

Dr. Busin described a modified DSAEK technique developed by his group that resulted in rates of donor endothelial cells survival equivalent to PK.

"Our approach reduced the rate of endothelial cell loss in the transplanted tissue to an average of 23% at one year post-surgery, which is similar to values recorded after PK," said Dr. Busin. "Our 'pull through' tech
'/>"/>

SOURCE American Academy of Ophthalmology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
4. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
5. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
8. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
9. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
10. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...., Dec. 1 Former New Jer...elighted when his radiotherapy treatment sessions ...h day to less than five. Midway through his cours...ology Cancer Center acquired the region,s first ...an Medical Systems (NYSE: VAR ), making it possi...
(Date:12/1/2009)..., Dec. 1 The educational...h... Improving Life," created by Lilly USA (NYSE: ...alth.com/value_of_medicine.jsp . The booklet suppo...Matter" and encourages an open dialogue with patie...ceutical industry practices. ,, "Today, Lilly ...
(Date:12/1/2009)...e-FirstCall/ -- WebMD Health Corp. (Nasdaq: WBMD ... announced the honorees of the 2009 WebMD Health H...s honor Americans with extraordinary stories of pe...t to help others achieve better health. ,, ...1201/NY18114 ) ,, "WebMD is honoring its 2009 ...
Breaking Medicine Technology:Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 2Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 3Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 4Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 5Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 2Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 3Lilly Releases Latest 'Value of Medicine' Resource Guide About Key Issues Facing the Pharmaceutical Industry 4WebMD Announces 2009 Health Heroes 2WebMD Announces 2009 Health Heroes 3ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities 5342 1ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities 5342 2ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities 5342 3Mirixa Corporation Announces Key Pharmacy Network Hire 5339 1Mirixa Corporation Announces Key Pharmacy Network Hire 5339 2AST on Capitol Hill to Promote Transplant Drug Extension Provision With Senate as Part of Health Care Reform 5336 1AST on Capitol Hill to Promote Transplant Drug Extension Provision With Senate as Part of Health Care Reform 5336 2
...nical Trial in Type 2,Diabetes Patients Announced,...ransition,Therapeutics Inc. ("Transition") , today...IIa clinical trial indicating that 4-weeks of,dail...(TM), showed,sustained reductions in blood glucose...1c), for 6 months post-treatment. The type 2,diabe...
...07 - Cytogen,Corporation (NASDAQ: CYTO) reported u...valuating QUADRAMET(R) (samarium Sm-153,lexidronam...e(R),Millennium Pharmaceuticals, Inc.) in patient...ients were presented today in a,poster titled, "Ph... in Multiple Myeloma," by James Berenson, M.D., Me...
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8
(Date:12/1/2009)...EW ORLEANS, Dec. 1 The ... annual High School Student Symposium at the New O....m. CST. The symposium, which encourages an intere...ical research, is held in conjunction with the Soc...ll have the opportunity to explore research on sic...
(Date:12/1/2009)... BANK, N.J., Dec. 1 A national sur...ding is ideal for their babies and themselves but ...ks best for them and their families. ,, See vid...IFC_37156/ ,, The survey of mothers of childre...rs (83%) made their infant feeding decision prior ...
(Date:12/1/2009)...d in development of simple screening test, expert ...) -- In a finding that could lead to a simple bloo... have identified immune system markers that indica...for lung cancer. , The researchers examined gen...ople with non-small cell lung cancer and a contro...
(Date:12/1/2009)...cination because pandemic,s course remains unpredi...ws) -- A U.S. health official said Tuesday that H1...ationally, but many experts agreed the virus could...s now widespread in 32 states -- down from 43 stat...r of the U.S. Centers for Disease Control and Prev...
(Date:12/1/2009)... Ever thought you could quit smoking while ...ith,s groundbreaking new system for quitting is ea...just twenty eight days your cravings and desire to... (PRWEB) December 1, 2009 -- Izabella ha...ear addiction to nicotine, smoking at least a pack...
Breaking Medicine News(10 mins):Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3Health News:VIDEO from Medialink and HealthyWomen: Breast, Bottle or Both? 2Health News:Gene 'Signature' May Point to Lung Cancer 2Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 2Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 3
...l new studies on genetics and stem cell research, ... of stents to clear coronary artery blockages are ...nd stroke for 2007, said Daniel W. Jones, M.D., pr...opulmonary resuscitation. , The American Heart Ass...
...N, Dec. 20 The following is being,issued by Cente...pproaching, millions of Americans are preparing,to...tree-trimming, and,leaving cookies and milk out fo...of a very un-merry obesity lawsuit., Before he wo...
...b., Dec. 20 Alegent Health is once,again taking t... making it,possible for consumers on the go to rec...tions -- even pictures of newborns delivered at on...nd PDAs,to access., "The latest research suggests...
...ES, Dec. 20 By a landslide 87 percent vote,regist... the Los Angeles,area Wednesday night elected the ...ses Association/National Nurses Organizing Committ...NNOC will represent 300 RNs at,the hospital., Fol...
...DGE, Tenn., Dec. 20, 2007 -- A Las Vegas business ...e odds for people medically at risk from dehydrati...NL researchers Chuck Britton, Nance Ericson and Ga...his is of great importance to members of the milit...
..., N.C., Dec. 20 MedCath Corporation,(Nasdaq: MDT...ned as,Executive Vice President and Chief Financia...r Charlotte, N.C. based Coca-Cola Bottling Co.,Con...ll remain with MedCath until near the end of Janua...
Other Medicine News:Health News:Top10 research advances include studies on genetics and stem cell research, stents 2Health News:Top10 research advances include studies on genetics and stem cell research, stents 3Health News:Top10 research advances include studies on genetics and stem cell research, stents 4Health News:Top10 research advances include studies on genetics and stem cell research, stents 5Health News:Center for Consumer Freedom Releases 'Don't Sue Me Santa' Christmas Cookie Liability Waiver 2Health News:Alegent.com Goes Mobile 2Health News:Whittier Hospital RNs Choose CNA/NNOC in Landslide 87% Election Victory 2Health News:Nevada company, ORNL develop potential lifesaver 2Health News:James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated 2
Bra With Cups
Bandeau Bra
Medical Cotton Bra
Compression Bra
Medicine Products: